和远气体(002971) - 2020 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2020 was ¥101,466,306.28, a decrease of 30.00% compared to ¥144,946,162.70 in the same period last year[7] - Net profit attributable to shareholders was ¥10,737,342.78, down 38.65% from ¥17,500,976.72 year-on-year[7] - Basic and diluted earnings per share were both ¥0.07, representing a decrease of 53.33% from ¥0.15 in the same period last year[7] - Operating revenue decreased by 30.00% to CNY 101.47 million, primarily due to reduced sales in the industrial gas business caused by the COVID-19 pandemic[18] - The company's operating revenue for the current period is CNY 48,340,416.16, a decrease from CNY 81,314,325.06 in the previous period[52] - The net profit for the current period is CNY 4,013,609.78, compared to a net loss of CNY 162,221.41 in the previous period, indicating a significant turnaround[53] - The company reported a total comprehensive income of CNY 4,013,609.78 for the current period, compared to a total comprehensive loss of CNY 162,221.41 in the previous period[54] Cash Flow and Liquidity - The net cash flow from operating activities was -¥70,850,557.70, a decline of 556.15% compared to ¥15,532,171.73 in the previous year[7] - The cash flow from operating activities shows a net outflow of CNY 70,850,557.70, compared to a net inflow of CNY 15,532,171.73 in the previous period[57] - Cash inflow from operating activities totaled 45,954,783.40 yuan, while cash outflow reached 161,991,513.10 yuan, resulting in a net cash outflow[60] - The net increase in cash and cash equivalents was 411,033,532.59 yuan, compared to a decrease of -8,399,815.88 yuan in the previous period[61] - The ending balance of cash and cash equivalents was 427,414,104.75 yuan, significantly higher than the previous period's balance of 2,078,591.43 yuan[61] Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,807,527,048.79, an increase of 47.56% from ¥1,224,965,544.53 at the end of the previous year[7] - The company's total liabilities rose to ¥791,408,958.38, compared to ¥613,220,659.48, representing an increase of about 29.2%[41] - The company's equity increased significantly, with the share capital rising to ¥160,000,000.00 from ¥120,000,000.00, a growth of 33.3%[41] - Current assets increased to CNY 1,043,659,331.78 from CNY 475,438,252.94, reflecting a growth of approximately 119%[44] Shareholder Information - The company reported a total of 22,206 common shareholders at the end of the reporting period[11] - The largest shareholder, Yang Tao, holds 20.97% of the shares, totaling 33,549,769 shares[11] - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[12] Non-Operating Income and Expenses - Non-operating income included government subsidies of ¥575,904.53 and losses from non-normal work stoppages during the pandemic amounting to -¥2,044,691.37[8] - The company reported a significant increase in non-operating expenses by 584.17% to CNY 2.24 million, due to losses from non-normal operations of subsidiaries during the pandemic[18] Research and Development - Research and development expenses fell by 44.13% to CNY 1.35 million, reflecting a decrease in R&D activities due to the pandemic[18] - The company reported a decrease in research and development expenses to CNY 1,345,801.93 from CNY 2,408,817.00, a reduction of about 44%[48] Fundraising and Investments - The company received CNY 404.67 million from fundraising activities following its listing, significantly boosting its cash flow[20] - The company obtained a policy loan of CNY 200 million to expand medical oxygen production capacity, reflecting its strategic focus on healthcare during the pandemic[23] - The company has raised CNY 404,668,000.00 from new investments during the current period[58] Other Financial Metrics - The company's cash and cash equivalents increased by 800.91% to approximately CNY 445.96 million due to net fundraising of CNY 391 million from its listing on the Shenzhen Stock Exchange and receiving a policy loan of CNY 200 million[16] - Accounts receivable rose by 35.14% to CNY 113.06 million, impacted by poor sales collection during the COVID-19 pandemic and the Spring Festival holiday[16] - Prepayments surged by 533.21% to CNY 71.72 million as the company prepaid electricity and gas procurement costs to ensure medical oxygen supply during the pandemic[16]